157 related articles for article (PubMed ID: 33443094)
1. Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12.
Lewis ND; Sia CL; Kirwin K; Haupt S; Mahimkar G; Zi T; Xu K; Dooley K; Jang SC; Choi B; Boutin A; Grube A; McCoy C; Sanchez-Salazar J; Doherty M; Gaidukov L; Estes S; Economides KD; Williams DE; Sathyanarayanan S
Mol Cancer Ther; 2021 Mar; 20(3):523-534. PubMed ID: 33443094
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy.
Garaulet G; Pérez-Chacon G; Alarcón H; Alfranca A; Mulero F; Martínez-Torrecuadrada J; Zapata JM; Rodríguez A
Cancer Gene Ther; 2019 Jul; 26(7-8):216-233. PubMed ID: 30622324
[TBL] [Abstract][Full Text] [Related]
3. XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies.
Patel E; Malkova NV; Crowe D; Pederzoli-Ribeil M; Fantini D; Fanny M; Madala HR; Jenkins KA; Yerov O; Greene J; Guzman W; O'Toole C; Taylor J; O'Donnell RK; Johnson P; Lanter BB; Ames B; Chen J; Vu S; Wu HJ; Cantin S; McLaughlin M; Hsiao YS; Tomar DS; Rozenfeld R; Thiruneelakantapillai L; O'Hagan RC; Nicholson B; O'Neil J; Bialucha CU
Mol Cancer Ther; 2024 Apr; 23(4):421-435. PubMed ID: 38030380
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.
Cavallo F; Signorelli P; Giovarelli M; Musiani P; Modesti A; Brunda MJ; Colombo MP; Forni G
J Natl Cancer Inst; 1997 Jul; 89(14):1049-58. PubMed ID: 9230887
[TBL] [Abstract][Full Text] [Related]
5. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.
Melero I; Quetglas JI; Reboredo M; Dubrot J; Rodriguez-Madoz JR; Mancheño U; Casales E; Riezu-Boj JI; Ruiz-Guillen M; Ochoa MC; Sanmamed MF; Thieblemont N; Smerdou C; Hervas-Stubbs S
Cancer Res; 2015 Feb; 75(3):497-507. PubMed ID: 25527611
[TBL] [Abstract][Full Text] [Related]
6. Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold.
Gasparri AM; Sacchi A; Basso V; Cortesi F; Freschi M; Rrapaj E; Bellone M; Casorati G; Dellabona P; Mondino A; Corti A; Curnis F
Small; 2019 Nov; 15(45):e1903462. PubMed ID: 31523920
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity.
Han M; Nguyen B; Lee JY; Browning E; Zhang J; Mukhopadhyay A; Gujar R; Salazar J; Hermiz R; Svenson L; Rolig AS; Redmond WL; Algazi AP; Daud AI; Canton DA; Twitty CG
Mol Cancer Res; 2022 Jun; 20(6):983-995. PubMed ID: 35302641
[TBL] [Abstract][Full Text] [Related]
8. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
[TBL] [Abstract][Full Text] [Related]
9. Engineered Mesenchymal Stem Cells as a Biotherapy Platform for Targeted Photodynamic Immunotherapy of Breast Cancer.
Zhang H; Feng Y; Xie X; Song T; Yang G; Su Q; Li T; Li S; Wu C; You F; Liu Y; Yang H
Adv Healthc Mater; 2022 Mar; 11(6):e2101375. PubMed ID: 34981675
[TBL] [Abstract][Full Text] [Related]
10. CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect.
Xu HY; Li N; Yao N; Xu XF; Wang HX; Liu XY; Zhang Y
Oncol Rep; 2019 Aug; 42(2):866-879. PubMed ID: 31233203
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral injection of dendritic cells overexpressing interleukin‑12 inhibits melanoma growth.
Yao W; Li Y; Zeng L; Zhang X; Zhou Z; Zheng M; Wan H
Oncol Rep; 2019 Jul; 42(1):370-376. PubMed ID: 31115558
[TBL] [Abstract][Full Text] [Related]
12. The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Fallon J; Tighe R; Kradjian G; Guzman W; Bernhardt A; Neuteboom B; Lan Y; Sabzevari H; Schlom J; Greiner JW
Oncotarget; 2014 Apr; 5(7):1869-84. PubMed ID: 24681847
[TBL] [Abstract][Full Text] [Related]
13. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.
Paoloni M; Mazcko C; Selting K; Lana S; Barber L; Phillips J; Skorupski K; Vail D; Wilson H; Biller B; Avery A; Kiupel M; LeBlanc A; Bernhardt A; Brunkhorst B; Tighe R; Khanna C
PLoS One; 2015; 10(6):e0129954. PubMed ID: 26091536
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
Ahn HM; Hong J; Yun CO
Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
[TBL] [Abstract][Full Text] [Related]
15. Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer.
Li S; Zhang L; Torrero M; Cannon M; Barret R
Mol Ther; 2005 Nov; 12(5):942-9. PubMed ID: 15953768
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
Oh E; Choi IK; Hong J; Yun CO
Oncotarget; 2017 Jan; 8(3):4730-4746. PubMed ID: 28002796
[TBL] [Abstract][Full Text] [Related]
18. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
19. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
20. Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.
Parra-Guillen ZP; Janda A; Alzuguren P; Berraondo P; Hernandez-Alcoceba R; Troconiz IF
AAPS J; 2013 Jan; 15(1):183-94. PubMed ID: 23135926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
